FAP-Associated Desmoid Tumours

Chapter
Part of the M.D. Anderson Solid Tumor Oncology Series book series (MDA, volume 5)

Abstract

Desmoid tumours are rare and may occur spontaneously or in association with FAP (familial adenomatous polyposis). In both settings trauma as a trigger for growth initiation has been postulated. They differ in their predominant localisation, whereas differences in biological behaviour or response to therapeutic approaches have yet to be delineated. In all cases the tumour is frequently not recognized and treatment options are not being weighed thoroughly. Frequent debulking procedures lead to more aggressive growth and high morbidity and mortality. For the majority of desmoid tumours a less aggressive therapeutic approach may be more benefical in the long-term results, especially for desmoids occurring in the mesentery of FAP patients, that have already been subjected to colectomy.

Keywords

Familial adenomatous polyposis (FAP) Extracolonic manifestation Desmoid tumour Aggressive fibromatosis 

References

  1. 1.
    Muller J. Ueber den feinen Bau und die Formen der krankhaften Geschwulste (About the fine structure and types of pathological tumours). Berlin: Reimer G Erste Lieferung; 1838. p. 6β.Google Scholar
  2. 2.
    Naylor EW, Gardner EJ, Richards RC. Desmoid tumors and mesenteric fibromatosis in Gardner’s syndrome: report of kindred 109. Arch Surg. 1979;114:1181–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Reitamo JJ, Hayry P, Nykyri E, Saxen E. The desmoid tumor. Incidence, sex, age and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982;77:665–73.PubMedGoogle Scholar
  4. 4.
    Farmer KC, Hawley PR, Phillips RK. Desmoid disease. In: Phillips RK, Spigelman AD, Thomson JP, editors. Familial adenomatous polyposis and other polyposis syndromes. London: Edward Arnold; 1994. p. 128–42.Google Scholar
  5. 5.
    Nichols RW. Desmoid tumors: a report of 31 cases. Arch Surg. 1923;7:227–36.CrossRefGoogle Scholar
  6. 6.
    Gardner EJ. A genetic and clinical study of intestinal polyposis, a predisposing factor for carcinoma of the colon and rectum. Am J Hum Genet. 1951;3:167–76.PubMedGoogle Scholar
  7. 7.
    Smith WG. Multiple polyposis, Gardner’s syndrome, and desmoid tumors. Dis Colon Rectum. 1958;1:323–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Rodriguez-Bigas MA, Mahoney MC, Karakousis CP, Petrelli NJ. Desmoid tumors in patients with familial adenomatous polyposis. Cancer. 1994;74:1270–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Belchetz LA, Berk T, Bapat BV, Cohen Z, Gallinger S. Changing causes of mortality in patients with FAP. Dis Colon Rectum. 1996;39:384–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Cheon SS, Cheah AY, Turley S. Beta-Catenin stabilization deregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci USA. 2002;99:6973–078.PubMedCrossRefGoogle Scholar
  11. 11.
    Tejpar S, Michils G, Denys H. Analysis of Wnt/beta catenin signalling in desmoids tumours. Acta Gastroenterol Belg. 2005;68:5–9.PubMedGoogle Scholar
  12. 12.
    Tejpar S, Li C, Yu C. Tcf-3 expression and beta-catenin mediated transcriptional activation in aggressive fibromatosis (desmoids tumour). Br J Cancer. 2001;85:98–101.PubMedCrossRefGoogle Scholar
  13. 13.
    Leithner A, Gapp M, Radl R. Immunohistochemical analysis of desmoids tumours. J Clin Pathol. 2005;58:1152–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Peterschulte G, Lickfeld T, Moeslein G. The desmoid problem. Chirurg. 2000;71:894–900.PubMedCrossRefGoogle Scholar
  15. 15.
    Church J, Berk T, Bomann BM, et al. Collaborative group of the Americas on inherited ­colorectal cancer. Staging intraabdominal desmoids tumours in familial adenomatous polyposis: a search for a uniform approach to a troubling disease. Dis Colon Rectum. 2005;48:1528–34.PubMedCrossRefGoogle Scholar
  16. 16.
    Skene AI, Barr L, A’Hern RP, Fisher C, Meirion Thomas J. Multimodality treatment in the control of deep musculoaponeurotic fibromatosis. Br J Surg. 1998;85(5):655–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Castellazi G, Vanel D, Le Cesne A, Le Pechoux C, Perona F, Bonvalot S. Can the MRI signal of aggressive fibromatosis be used to predict its behaviour? Eur J Radiol. 2009;69(2):222–9.CrossRefGoogle Scholar
  18. 18.
    Posner MC, Shiu MH, Newsome JL, et al. The desmoid tumor: not a benign disease. Arch Surg. 1989;124:191–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ, Brennan MF. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg. 2002;235:424–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Merchant NB, Lewis JJ, Woodruff JM, Leung DH, Brennan MF. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer. 1999;86:2045–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Sorenson A, Keller J, Nielsen O, Jensen O. Treatment of aggressive fibromatosis. A retrospective study of 72 patients followed for 1–27 years. Acta Orthop Scand. 2002;73:213–9.CrossRefGoogle Scholar
  22. 22.
    Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol. 2003;21:1390–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Phillips SR, A’Hern R, Thomas JM. Aggressive fibromatosis of the abdominal wall, limbs and limb girdles. Br J Surg. 2004;91:1624–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Clark SK, Neale KF, Landgrebe JC, Phillips RKS. Desmoid tumours complicating familial adenomatous polyposis. Br J Surg. 1999;86:1185–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Phillips RKS, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002;50:857–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Friend WG. Sulindac suppression of colorectal polyps in Gardener’s syndrome. Am Fam Physician. 1990;41:891–4.PubMedGoogle Scholar
  27. 27.
    Tsukada K, Church JM, Jagelman DG, et al. Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum. 1992;35(1):29–33.PubMedCrossRefGoogle Scholar
  28. 28.
    Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004;100(3):612–20.PubMedCrossRefGoogle Scholar
  29. 29.
    Poon R, Smits R, Li C, et al. Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene. 2001;20(4):451–60.PubMedCrossRefGoogle Scholar
  30. 30.
    Tonelli F, Ficari F, Valanzano R, Brandi ML. Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumori. 2003;89(4):391–6.PubMedGoogle Scholar
  31. 31.
    Janinis J, Patriki M, Vini L, et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol. 2003;14(2):181–90.PubMedCrossRefGoogle Scholar
  32. 32.
    Lindor NM, Dozois R, Nelson H, et al. Desmoid tumors in familial adenomatous polyposis: a pilot project evaluating efficacy of treatment with pirfenidone. Am J Gastroenterol. 2003;98(8):1868–74.PubMedCrossRefGoogle Scholar
  33. 33.
    Mace J, Sybil Biermann J, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer. 2002;95(11):2373–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Leithner A, Gapp M, Radl R, et al. Immunohistochemical anaöysis of desmoid tumours. J Clin Pathol. 2005;58:1152–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Heinrich M, McArthur G, Demetri G, et al. Clinical and molecular studies of the effect of Imatinib on advanced aggressive fibromatosis (desmoid tumour). J Clin Oncol. 2006;24:1195–203.PubMedCrossRefGoogle Scholar
  36. 36.
    Seiter K, Kemeny N. Successful treatment of a desmoid tumour with doxorubicin. Cancer. 1993;71:2242–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Risum S, Bulow S. Doxorubicin treatment of an intra-abdominal desmoid tumour in a patient with familial adenomatous polyposis. Colorectal Dis. 2003;5(6):585–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Weiss A, Lackman R. Low-dose chemotherapy of desmoid tumours. Cancer. 1989;64:1192–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer. 2001;92(5):1259–64.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.HELIOS St. Josefs-Hospital Bochum-LindenBochumGermany

Personalised recommendations